ES2860952T3 - Proteína anti-garp y usos de la misma - Google Patents

Proteína anti-garp y usos de la misma Download PDF

Info

Publication number
ES2860952T3
ES2860952T3 ES14748185T ES14748185T ES2860952T3 ES 2860952 T3 ES2860952 T3 ES 2860952T3 ES 14748185 T ES14748185 T ES 14748185T ES 14748185 T ES14748185 T ES 14748185T ES 2860952 T3 ES2860952 T3 ES 2860952T3
Authority
ES
Spain
Prior art keywords
antibody
seq
hgarp
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14748185T
Other languages
English (en)
Spanish (es)
Inventor
Sophie Lucas
Pierre Coulie
Villasur Julia Cuende
Laure Dumoutier
Jean-Christophe Renauld
Der Woning Sebastian Van
Michael Saunders
Haard Hans De
Boeck Gitte De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
ArgenX BVBA
Ludwig Institute for Cancer Research Ltd
Original Assignee
Universite Catholique de Louvain UCL
ArgenX BVBA
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP13178958.8A external-priority patent/EP2832747A1/en
Application filed by Universite Catholique de Louvain UCL, ArgenX BVBA, Ludwig Institute for Cancer Research Ltd filed Critical Universite Catholique de Louvain UCL
Application granted granted Critical
Publication of ES2860952T3 publication Critical patent/ES2860952T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
ES14748185T 2013-08-01 2014-08-01 Proteína anti-garp y usos de la misma Active ES2860952T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361861008P 2013-08-01 2013-08-01
EP13178958.8A EP2832747A1 (en) 2013-08-01 2013-08-01 Anti-GARP protein and uses thereof
EP14167425 2014-05-07
PCT/EP2014/066650 WO2015015003A1 (en) 2013-08-01 2014-08-01 Anti-garp protein and uses thereof

Publications (1)

Publication Number Publication Date
ES2860952T3 true ES2860952T3 (es) 2021-10-05

Family

ID=52431038

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14748185T Active ES2860952T3 (es) 2013-08-01 2014-08-01 Proteína anti-garp y usos de la misma

Country Status (16)

Country Link
US (5) US10000572B2 (OSRAM)
EP (2) EP3027650B1 (OSRAM)
JP (3) JP2016529892A (OSRAM)
KR (2) KR20220025174A (OSRAM)
CN (2) CN113583128A (OSRAM)
AU (3) AU2014298373B2 (OSRAM)
BR (1) BR112016002199B8 (OSRAM)
CA (1) CA2919765C (OSRAM)
EA (1) EA035550B1 (OSRAM)
ES (1) ES2860952T3 (OSRAM)
IL (2) IL243899B (OSRAM)
MX (2) MX377091B (OSRAM)
NZ (1) NZ717476A (OSRAM)
SG (2) SG11201600741SA (OSRAM)
WO (1) WO2015015003A1 (OSRAM)
ZA (1) ZA201601085B (OSRAM)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052232T2 (hu) 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
KR20220025174A (ko) * 2013-08-01 2022-03-03 위니베르시트카솔리끄드루뱅 항garp 단백질 항체와 그 용도
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
WO2017013276A1 (es) * 2015-07-22 2017-01-26 Hospital Sant Joan De Deu Inmunoterapia para el cáncer con expresión de casr (p. ej. neuroblastoma)
EP4349997A3 (en) * 2015-09-24 2024-07-10 Daiichi Sankyo Company, Limited Anti-garp antibody
MX2018006613A (es) * 2015-12-02 2019-01-30 Stcube & Co Inc Anticuerpos y moleculas que se unen inmunoespecificamente a btn1a1 y los usos terapeuticos de los mismos.
PL3365368T3 (pl) * 2016-03-11 2023-08-21 Scholar Rock, Inc. Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
US11046782B2 (en) 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
US10100106B2 (en) 2016-05-20 2018-10-16 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
MX419976B (es) * 2016-07-14 2025-01-14 Scholar Rock Inc Anticuerpos de tgfb, métodos, y usos
EP3568466A4 (en) 2017-01-10 2020-07-15 The General Hospital Corporation TARGETED T CELLS WITH CYTOTOXICITY TO IMMUNOSUPPRESSIVE CELLS
CA3059444A1 (en) * 2017-04-14 2018-10-18 The General Hospital Corporation Chimeric antigen receptor t cells targeting the tumor microenvironment
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
SI3694529T1 (sl) 2017-10-13 2024-10-30 Harpoon Therapeutics, Inc. Trispecifične beljakovine in načini uporabe
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
WO2019157533A1 (en) * 2018-02-12 2019-08-15 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
AU2019363368A1 (en) * 2018-10-16 2021-05-13 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies
EP3902823A1 (en) 2018-12-24 2021-11-03 Sanofi Multispecific binding proteins with mutant fab domains
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AR119594A1 (es) 2019-08-09 2021-12-29 Gilead Sciences Inc Derivados de tienopirimidina como inhibidores acc y usos de los mismos
JPWO2021079958A1 (OSRAM) * 2019-10-25 2021-04-29
AU2020384883B2 (en) 2019-11-15 2023-11-16 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
JP7511377B2 (ja) * 2020-04-16 2024-07-05 デンカ株式会社 アデノウイルスの免疫測定方法及び免疫測定器具
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
JP7591066B2 (ja) 2020-06-03 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
WO2022116877A1 (en) 2020-12-02 2022-06-09 Shanghai Henlius Biotech, Inc. ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
JP2024502670A (ja) * 2021-01-18 2024-01-22 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド Ｇａｒｐタンパク質抗体及びその適用
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022240879A1 (en) 2021-05-11 2022-11-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
KR20240007233A (ko) 2021-05-13 2024-01-16 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제 및 이의 용도
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
EP4416184A4 (en) * 2021-10-11 2025-11-19 Ohio State Innovation Foundation Glycoprotein Predominantly Repeating Antibodies (GARP) and Their Uses
JP7709612B2 (ja) 2021-12-08 2025-07-16 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
AU2022419982B2 (en) 2021-12-22 2026-04-16 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
GB202203269D0 (en) 2022-03-09 2022-04-20 Argenx Iip Bv TGF-Beta antibodies
EP4493554A1 (en) 2022-03-17 2025-01-22 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4558823A1 (en) 2022-07-22 2025-05-28 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
WO2024023797A1 (en) 2022-07-29 2024-02-01 Abbvie Biotherapeutics Inc. ANTI-GARP-TGF-β1/PD-1 COMBINATION THERAPY
EP4634224A1 (en) 2022-12-14 2025-10-22 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
KR20260022341A (ko) * 2023-06-05 2026-02-19 퓨어 바이올로직스 스푸우카 아크치이나 항 garp 항체 및 이의 사용 방법
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AR134560A1 (es) 2023-12-08 2026-01-28 Astellas Pharma Inc Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) 2024-08-08 2026-02-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026089992A1 (en) 2024-10-21 2026-04-30 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
NZ298145A (en) * 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
CN1333274A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人garp蛋白12.98和编码这种多肽的多核苷酸
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
EP2001509A1 (en) 2006-04-03 2008-12-17 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
CN101808664A (zh) * 2007-08-24 2010-08-18 学校法人庆应义墪 肿瘤细胞所导致的免疫抑制的解除剂及使用该解除剂的抗肿瘤剂
WO2009055054A2 (en) * 2007-10-25 2009-04-30 Janda Kim D Antibody-mediated disruption of quorum sensing in bacteria
WO2009073163A1 (en) * 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
US20100303828A1 (en) * 2008-01-31 2010-12-02 INSERM Institut National de la Sante et de la Recherche Medicale) Antibodies Against Human CD39 and Use Thereof for Inhibiting T Regulatory Cells Activity
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8951793B2 (en) 2008-08-21 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of making an isolated population of FOXP3+ regulatory T cells
EP2977386A1 (en) 2012-08-31 2016-01-27 Argen-X Nv Method for producing antibody molecules having inter-species, intra-target cross-reactivity
HUE052232T2 (hu) * 2013-05-06 2021-04-28 Scholar Rock Inc Készítmények és eljárások növekedési faktor modulálására
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
KR20220025174A (ko) 2013-08-01 2022-03-03 위니베르시트카솔리끄드루뱅 항garp 단백질 항체와 그 용도
WO2016125017A1 (en) 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
EP4349997A3 (en) 2015-09-24 2024-07-10 Daiichi Sankyo Company, Limited Anti-garp antibody
MX419976B (es) 2016-07-14 2025-01-14 Scholar Rock Inc Anticuerpos de tgfb, métodos, y usos

Also Published As

Publication number Publication date
AU2014298373A1 (en) 2016-02-18
SG11201600741SA (en) 2016-02-26
CN105658666A (zh) 2016-06-08
US10000572B2 (en) 2018-06-19
EA201690314A1 (ru) 2016-07-29
US10604579B2 (en) 2020-03-31
US11230603B2 (en) 2022-01-25
US20190016811A1 (en) 2019-01-17
JP2020073504A (ja) 2020-05-14
US20200087404A1 (en) 2020-03-19
US20160251438A1 (en) 2016-09-01
CA2919765C (en) 2023-03-21
CA2919765A1 (en) 2015-02-05
IL276106A (en) 2020-08-31
MX2016001356A (es) 2016-10-26
EA035550B1 (ru) 2020-07-06
JP2016529892A (ja) 2016-09-29
AU2021277761A1 (en) 2021-12-23
IL243899A0 (en) 2016-04-21
US20160272717A1 (en) 2016-09-22
MX2019011952A (es) 2019-12-05
KR102362609B1 (ko) 2022-02-11
IL243899B (en) 2020-07-30
KR20220025174A (ko) 2022-03-03
BR112016002199A2 (pt) 2017-08-29
WO2015015003A1 (en) 2015-02-05
EP3027650A1 (en) 2016-06-08
KR20160056880A (ko) 2016-05-20
CN105658666B (zh) 2021-07-27
AU2019268046A1 (en) 2019-12-05
ZA201601085B (en) 2022-09-28
NZ717476A (en) 2022-04-29
SG10201800889SA (en) 2018-03-28
MX377091B (es) 2025-03-07
CN113583128A (zh) 2021-11-02
JP2022070946A (ja) 2022-05-13
US10822424B2 (en) 2020-11-03
BR112016002199B8 (pt) 2024-03-05
US20200181276A1 (en) 2020-06-11
EP3786187A1 (en) 2021-03-03
JP7492981B2 (ja) 2024-05-30
BR112016002199B1 (pt) 2023-10-17
AU2014298373B2 (en) 2019-12-05
EP3027650B1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
JP7492981B2 (ja) 抗ｇａｒｐタンパク質及びその使用
WO2016125017A1 (en) Anti-garp protein and uses thereof
ES2921015T3 (es) Anticuerpos contra GARP-TGF-BETA
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
EP2832747A1 (en) Anti-GARP protein and uses thereof
WO2022100613A1 (zh) 针对密蛋白18a2和cd3的双特异性抗体及其应用
JP2021501120A (ja) 抗ガレクチン−９抗体及びその使用
KR20180030856A (ko) 인간 cd3 결합 항체
ES2737307T3 (es) Anticuerpos no antagonistas dirigidos contra la cadena alfa del dominio extracelular del receptor de IL7 y uso del mismo en el tratamiento del cáncer
WO2023006040A1 (zh) 抗pvrig/抗tigit双特异性抗体和应用
CN114907479A (zh) 抗cd112r抗体及其用途
TW202144429A (zh) 抗ｃｄ２５抗體、其抗原結合片段及其醫藥用途
JP2025540657A (ja) 抗ｃｄ３抗体
HK1225391A1 (en) Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1
HK1225391B (en) Antibody binding a complex of human glycoprotein a repetitions predominant (garp) and latent tgf-beta-1
WO2025228351A1 (zh) 抗体，抗体药物偶联物及其用途
TW202436350A (zh) 抗ｌｉｌｒｂ１及／或抗ｌｉｌｒｂ２抗體及其等用途
HK40066457A (zh) 两种以上抗-c5抗体的组合与使用方法
CN120659811A (zh) 双特异性抗原结合分子及其应用